Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study | Zendy

Shih-Chieh Chien | Zendy; Chiung-Yu Chen | Zendy; PinNan Cheng | Zendy; Yi-Shan Liu | Zendy; HsiuChi Cheng | Zendy; ChiaoHsiung Chuang | Zendy; TingTsung Chang | Zendy; Hong-Chi Chiu | Zendy; Yih-Jyh Lin | Zendy; YenCheng Chiu | Zendy

Open Access

Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study

Author(s) -

Shih-Chieh Chien,

Chiung-Yu Chen,

PinNan Cheng,

Yi-Shan Liu,

HsiuChi Cheng,

ChiaoHsiung Chuang,

TingTsung Chang,

Hong-Chi Chiu,

Yih-Jyh Lin,

YenCheng Chiu

Publication year - 2018

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.916

H-Index - 34

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000489790

Subject(s) - sorafenib , medicine , hepatocellular carcinoma , propensity score matching , liver function , liver cancer , gastroenterology , stage (stratigraphy) , proportional hazards model , oncology , response evaluation criteria in solid tumors , chemotherapy , progressive disease , paleontology , biology

Combining TA(C)E-based locoregional treatment with sorafenib resulted in better OS in patients with BCLC stage C HCC compared with sorafenib alone. TA(C)E-based locoregional treatment can be an adjunctive treatment to sorafenib for patients with advanced HCC and a satisfactory liver functional reserve.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research